Sugi Predict

Sugi Predict / Compounds / SCHEMBL2360520

SCHEMBL2360520

SCHEMBL2360520

O=C(O)c1cc(C(F)(F)F)[nH]n1

nearest known ligand 0.52

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ HCAR2 Q8TDS4 13/20 0.52
▸ DAO P14920 1/20 0.52
▸ ALOX15 P16050 2/20 0.49
▸ HCAR3 P49019 2/20 0.47
▸ CYTH3 O43739 1/20 0.47
▸ BTK Q06187 1/20 0.47
▸ EPN1 Q9Y6I3 1/20 0.47
▸ TP53 P04637 1/20 0.45
▸ MAPK1 P28482 1/20 0.45
▸ HSD17B10 Q99714 1/20 0.45
▸ RBP4 P02753 1/20 0.43
▸ NOTUM Q6P988 1/20 0.42
▸ HPGD P15428 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28860793 0.85 HCAR2 (0.53) HCAR2DAOHCAR3CYTH3BTK
SCHEMBL6757804 0.82 ALOX15 (0.48) ALOX15TP53MAPK1HSD17B10RBP4
SCHEMBL31308506 0.82 ALOX15 (0.48) ALOX15TP53MAPK1HSD17B10RBP4
SCHEMBL3053796 0.82 ALOX15 (0.51) ALOX15TP53MAPK1HSD17B10RBP4
SCHEMBL6371053 0.80 HCAR2 (0.57) HCAR2DAOHCAR3CYTH3BTK
SCHEMBL5600122 0.78 HCAR2 (0.55) HCAR2DAOHCAR3CYTH3BTK
SCHEMBL17894320 0.78 ALOX15 (0.45) ALOX15TP53MAPK1HSD17B10RBP4
SCHEMBL19780067 0.78 MAPK1 (0.59) ALOX15MAPK1RBP4NOTUMHPGD
SCHEMBL31464892 0.76 HCAR2 (0.47) HCAR2DAOHCAR3CYTH3BTK
SCHEMBL4619669 0.74 HCAR2 (0.54) HCAR2DAOHCAR3CYTH3BTK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12516046-B2 2-oxo-oxazolidine-5-carboxamides as NAV1.8 inhibitors MERCK SHARP & DOHME LLC (US) 2026-01-06 — — US disclosed
WO-2025096653-A1 COMPOSITIONS AND INHIBITORS OF POLRMT PRETZEL THERAPEUTICS, INC. (US) 2025-05-08 — — WO disclosed
WO-2025096657-A1 COMPOSITIONS AND INHIBITORS OF POLRMT PRETZEL THERAPEUTICS, INC. (US) 2025-05-08 — — WO disclosed
WO-2025096660-A1 COMPOSITIONS AND INHIBITORS OF POLRMT PRETZEL THERAPEUTICS, INC. (US) 2025-05-08 — — WO disclosed
WO-2025096654-A1 COMPOSITIONS AND INHIBITORS OF POLRMT PRETZEL THERAPEUTICS, INC. (US) 2025-05-08 — — WO disclosed
WO-2025096658-A1 COMPOSITIONS AND INHIBITORS OF POLRMT PRETZEL THERAPEUTICS, INC. (US) 2025-05-08 — — WO disclosed
WO-2025096662-A1 COMPOSITIONS AND INHIBITORS OF POLRMT PRETZEL THERAPEUTICS, INC. (US) 2025-05-08 — — WO disclosed
US-12264147-B2 Substituted carboxamides as inhibitors of WDR5 protein-protein binding Propellon Therapeutics Inc. (CA) 2025-04-01 — — US disclosed
EP-3885340-B1 ANDROGEN RECEPTOR MODULATING COMPOUNDS ORION CORP (FI) 2024-11-27 — — EP disclosed
US-20240246932-A1 ARYL 3-OXOPIPERAZINE CARBOXAMIDES AND HETEROARYL 3-OXOPIPERAZINE CARBOXAMIDES AS NAV1.8 INHIBITORS MERCK SHARP & DOHME LLC (US) 2024-07-25 — — US disclosed
WO-2010054763-A1 HETEROCYCLICALLY SUBSTITUTED ARYL COMPOUNDS AS HIF INHIBITORS BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-05-20 — — WO disclosed
WO-2010054764-A1 HETEROAROMATIC COMPOUNDS FOR USE AS HIF INHIBITORS BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-05-20 — — WO disclosed
WO-2010054762-A1 AMINOALKYL-SUBSTITUTED COMPOUNDS AS HIF INHIBITORS BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-05-20 — — WO disclosed
EP-2148877-A2 INHIBITORS OF HYPOXIA INDUCIBLE FACTOR (HIF) USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS Bayer Schering Pharma AG (DE) 2010-02-03 — — EP disclosed
US-20090143455-A1 Pyrazoles Useful in the Treatment of Inflammation BIOLIPOX AB (SE) 2009-06-04 — — US disclosed
CN-101331118-A Pyrazoles useful in the treatment of inflammation BIOLIPOX AB (SE) 2008-12-24 — — CN disclosed
WO-2008141731-A2 INHIBITORS OF HYPOXIA INDUCIBLE FACTOR (HIF) USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS BAYER HEALTHCARE AG (DE) 2008-11-27 — — WO disclosed
EP-1937645-A1 PYRAZOLES USEFUL IN THE TREATMENT OF INFLAMMATION Biolipox AB (SE) 2008-07-02 — — EP disclosed
US-20070225318-A1 Pyrazole Compounds Useful In The Treatment Of Inflammation BIOLIPOX AB (SE) 2007-09-27 — — US disclosed
WO-2007045868-A1 PYRAZOLES USEFUL IN THE TREATMENT OF INFLAMMATION BIOLIPOX AB (SE) 2007-04-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070225318-A1 Pyrazole Compounds Useful In The Treatment Of Inflammation ALOX15, ALOX15B, ALOX12 HCAR2 199/4885DAO 634/4885ALOX15 1/4885
US-12264147-B2 Substituted carboxamides as inhibitors of WDR5 protein-protein binding WDR5, WDR82, WDR1 HCAR2 2443/4885DAO 3012/4885ALOX15 4276/4885
US-20240246932-A1 ARYL 3-OXOPIPERAZINE CARBOXAMIDES AND HETEROARYL 3-OXOPIPERAZINE CARBOXAMIDES AS NAV1.8 INHIBITORS TRPV1, SCN8A, SCN2A HCAR2 367/4885DAO 4010/4885ALOX15 2110/4885
US-20090143455-A1 Pyrazoles Useful in the Treatment of Inflammation ALOX15, ALOX12, ALOX15B HCAR2 580/4885DAO 797/4885ALOX15 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.